

**Bibliography**

Papers of special note have been highlighted as either of interest (\*) or of considerable interest (\*\*) to readers.

1. Tamamura H, Tsurumi H. Specific probes for chemokine receptors. *Chem Biol* 2006;13:8-10
2. Tashiro K, Tada H, Heilker R, et al. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. *Science* 1993;261:600-3
3. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. *Proc Natl Acad Sci USA* 1994;91:2305-9
4. Oberlin E, Amara A, Bachelier F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. *Nature* 1996;382:833-5
5. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature* 1996;382:829-33
6. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* 1996;272:872-7
7. Koshida T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. *Clin Cancer Res* 2000;6:3530-5
8. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. *J Immunol* 2001;167:4747-57
9. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. *Nature* 2001;410:50-6
10. Robledo MM, Bartolome RA, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. *J Biol Chem* 2001;276:45098-105
11. Sanz-Rodriguez F, Hidalgo A, Teixeira J. Chemokine stromal cell-derived factor-1 $\alpha$  modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. *Blood* 2001;97:346-51
12. Scotton CJ, Wilson JL, Milliken D, et al. Epithelial cancer cell migration: a role for chemokine receptors? *Cancer Res* 2001;61:4961-5
13. Bertolini F, Dell'agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. *Cancer Res* 2002;62:3106-12
14. Kijima T, Maulik G, Ma PC, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. *Cancer Res* 2002;62:6304-11
15. Schrader AJ, Lechner O, Templin M, et al. CXCR4/CXCL12 expression and signaling in kidney cancer. *Br J Cancer* 2002;86:1250-6
16. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. *Cancer Res* 2002;62:5930-8
17. Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. *Cancer Res* 2002;62:1832-7
18. Burger M, Glodek A, Hartmann T, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. *Oncogene* 2003;22:8093-101
19. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. *Proc Natl Acad Sci USA* 2003;100:13513-8
20. Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. *FEBS Lett* 2003;550:79-83
21. Takenaga M, Tamamura H, Hiramatsu K, et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. *Biochem Biophys Res Commun* 2004;320:226-32
22. Mori T, Doi R, Koizumi K, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. *Mol Cancer Ther* 2004;3:29-37
23. Piovani E, Tosello V, Indraco S, et al. Chemokine receptor expression in EBV-associated lymphoproliferation in Hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. *Blood* 2005;105:931-9
24. Zannettino ACW, Farnugia AN, Kortisidis A, et al. Elevated serum levels of SDF-1 $\alpha$  are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. *Cancer Res* 2005;65:1700-9
25. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. *Blood* 1999;94:3658-67
26. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. *Leukemia* 2003;17:1294-300
27. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. *Blood* 2005;106:1824-30
28. Spoo A, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. *Blood* 2007;109:786-91
29. Nanki T, Hayashida K, El-Gabalawy HS, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4<sup>+</sup> T cell accumulation in rheumatoid arthritis synovium. *J Immunol* 2000;165:6590-8
30. Discovery of involvement of CXCR4 in rheumatoid arthritis.
31. \*\* The first report of in vivo suppression of cancer metastasis by biodegradable PLA microcapsules containing a T140 analogue.
32. \*\* The discovery of involvement of CXCR4 in tumor progression.
33. \*\* The discovery of involvement of CXCR4 in breast cancer metastasis.
34. \*\* First identification of CXCR4 antagonists as anticancer metastatic agents.

30. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. *J Biol Chem* 2005;280:35760-6
31. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J Exp Med* 2006;203:2201-13
32. Alkhatib G, Combadiere C, Broder CC, et al. A RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$  receptor as a fusion cofactor for macrophage-tropic HIV-1. *Science* 1996;272:1955-8
33. Choe H, Farzan M, Sun Y, et al. The  $\beta$ -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell* 1996;85:1135-48
34. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. *Nature* 1996;381:661-6
35. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the  $\beta$ -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. *Cell* 1996;85:1149-58
36. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. *Nature* 1996;381:667-73
37. Nakamura T, Furunaka H, Miyata T, et al. Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (*Tachyplesus tridentatus*). *J Biol Chem* 1988;263:16709-13
38. Miyata T, Tokunaga F, Yoneya T, et al. Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity. *J Biochem* 1989;106:663-8
39. Masuda M, Nakashima H, Ueda T, et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12, Lys7]-polyphemusin II). *Biochem Biophys Res Commun* 1992;189:845-50
40. Nakashima H, Masuda M, Murakami T, et al. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. *Antimicrob Agents Chemother* 1992;36:1249-55
41. Tamamura H, Xu Y, Hattori T, et al. A low molecular weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. *Biochem Biophys Res Commun* 1998;253:877-82
42. Murakami T, Nakajima T, Koyanagi Y, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. *J Exp Med* 1997;186:1389-93
43. Xu Y, Tamamura H, Arakaki R, et al. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. *AIDS Res Hum Retroviruses* 1999;15:419-27
44. Murakami T, Zhang T-Y, Koyanagi Y, et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. *J Virol* 1999;73:7489-96
45. Tamamura H, Sugioka M, Odagaki Y, et al. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. *Bioorg Med Chem Lett* 2001;11:359-62, 2409
46. Tamamura H, Omagari A, Oishi S, et al. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. *Bioorg Med Chem Lett* 2000;10:2633-7
47. Kanbara K, Sato S, Tanuma J, et al. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. *AIDS Res Hum Retroviruses* 2001;17:615-22
48. Tamamura H, Omagari A, Hiramatsu K, et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. *Bioorg Med Chem Lett* 2001;11:1897-902
49. Tamamura H, Hiramatsu K, Kusano S, et al. Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. *Org Biomol Chem* 2003;1:3656-62
50. Tamamura H, Hiramatsu K, Mizumoto M, et al. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. *Org Biomol Chem* 2003;1:3663-9
51. Ballewll F. The significance of cancer cell expression of the chemokine receptor CXCR4. *Semin Cancer Biol* 2004;14:171-9
52. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. *Cancer Res* 2002;62:7328-34
53. Tamamura H, Fujisawa M, Hiramatsu K, et al. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. *FEBS Lett* 2004;569:99-104
54. Fujii N, Oishi S, Hiramatsu K, et al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. *Angew Chem Int Ed Engl* 2003;42:3251-3
55. Ueda S, Oishi S, Wang Z, et al. Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. *J Med Chem* 2007;49:3412-5
56. Tamamura H, Esaka A, Ogawa T, et al. Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. *Org Biomol Chem* 2005;3:4392-4
57. Tamamura H, Tsutsumi H, Masuno H, et al. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs. *Org Biomol Chem* 2006;4:2354-7
58. Katoh M, Ueda S, Inuki S, et al. Identification of a new class of nonpeptide antagonists against chemokine receptor CXCR4. Abstracts of the 26th Medicinal
- **Discovery of a downsized CXCR4 antagonist, T140.**
- **Development of new leads of T140 analogues with biostability and high potency.**
- **The report of relevance of CXCR4 expression and malignant tumor cells.**
- **First identification of CXCR4 antagonists as anti-rheumatoid arthritis agents.**
- **The report of structure-activity relationships of cyclic pentapeptide CXCR4 antagonists.**
- **Development of low molecular weight CXCR4 antagonists.**
- **Development of linear type low molecular weight CXCR4 antagonists.**

## A future perspective on the development of chemokine receptor CXCR4 antagonists

- Chemistry Symposium, Sagamihara Japan 2007:2P-40
59. Ojida A, Mito-Oka Y, Sada K, et al. Molecular recognition and fluorescence sensing of monophosphorylated peptides in aqueous solution by bis(zinc(II)-dipicolylamine)-based artificial receptors. *J Am Chem Soc* 2004;126:2454-63
  60. Tamamura H, Ojida A, Ogawa T, et al. Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure. *J Med Chem* 2006;49:3412-5
  - **Development of linear type low molecular weight CXCR4 antagonists.**
  61. Demarco SJ, Henze H, Lederer A, et al. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. *Bioorg Med Chem* 2006;14:8396-404
  62. Mastrolorenzo A, Scozzafava A, Supuran CT. Small molecule antagonists of chemokine receptors as emerging anti-HIV agents. *Expert Opin Ther Patents* 2001;11:1245-52
  63. Scozzafava A, Mastrolorenzo A, Supuran CT. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. *J Enzyme Inhib Med Chem* 2002;17:69-76
  64. Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. *J Exp Med* 1997;186:1383-8
  65. De Clercq E. New anti-HIV agents and targets. *Med Res Rev* 2002;22:531-65
  66. Vermeire K, Hatse S, Princen K, et al. Virus resistance to the CXCR4 inhibitor AMD070 develops slowly and does not induce a co-receptor switch. *Antiviral Res* 2004;62:A42-3
  67. Gerlach LO, Jakobsen JS, Jensen KP, et al. Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. *Biochemistry* 2003;42:710-7
  68. Seibert C, Sakmar TP. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. *Curr Pharm Des* 2004;10:2041-62
  69. Doranz BJ, Grovit-Ferbas K, Sharron MP, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. *J Exp Med* 1997;186:1395-400
  70. Cabrera C, Gutierrez A, Barretina J, et al. Anti-HIV activity of a novel aminoglycoside-arginine conjugate. *Antiviral Res* 2002;53:1-8
  71. Cabrera C, Gutierrez A, Blanco J, et al. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. *AIDS Res Hum Retroviruses* 2000;16:627-34
  72. Daelemans D, Schols D, Witvrouw M, et al. A second target for the peptidic Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. *Mol Pharmacol* 2000;57:116-24
  73. Howard Omz, Oppenheim JJ, Hollingshead MG, et al. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. *J Med Chem* 1998;41:2184-93
  74. Zhan W, Liang Z, Zhu A, et al. Discovery of small molecule CXCR4 antagonists. *J Med Chem* 2007;50:5655-64
  75. Liu D-Y, Ye J-T, Yang W-H, et al. Ampelopsin, a small molecule inhibitor of HIV-1 infection targeting HIV entry. *Biomed Environ Sci* 2004;17:153-64
  76. Daoudi J-M, Greiner J, Aubertin A-M, Vierling P. New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity. *Bioorg Med Chem Lett* 2004;14:495-8
  77. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. *Proc Natl Acad Sci USA* 2003;100:4185-90
  78. Yamazaki T, Saitou A, Ono M, et al. WO029218; 2003
  79. Yamazaki T, Kikumoto S, Ono M, et al. WO024697; 2004
  80. Zou Y-R, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. *Nature* 1998;393:595-9
  81. Nakata H, Steinberg SM, Koh Y, et al. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. *Antimicrob Agents Chemother* 2008;52:2111-9
  - **The report concerning a combinational use of CXCR4/CCR5 antagonists.**
  82. Abraham M, Blyder K, Begin M, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. *Stem Cells* 2007;25:2158-66
  83. Broxmeyer HE, Orschell CM, Wade Clapp D, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. *J Exp Med* 2005;201:1307-18
  84. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. *Blood* 2003;102:2728-30
  85. Trent JO, Wang Z, Murray JL, et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. *J Biol Chem* 2003;278:47136-44

### Affiliation

Hirokazu Tamamura<sup>1,2</sup>, Hiroshi Tsutsumi<sup>1</sup>, Wataru Nomura<sup>1</sup>, Tomohiro Tanaka<sup>1</sup> & Nobutaka Fujii<sup>1</sup>

<sup>1</sup>Author for correspondence

<sup>1</sup>Tokyo Medical and Dental University, Institute of Biomaterials and Bioengineering, Chiyoda-ku, Tokyo 101-0062, Japan  
Tel: +81 3 5280 8036; Fax: +81 3 5280 8039; E-mail: tamamura.mr@tmd.ac.jp

<sup>2</sup>Tokyo Medical and Dental University, School of Biomedical Science, Chiyoda-ku, Tokyo 101-0062, Japan  
<sup>3</sup>Kyoto University,

Graduate School of Pharmaceutical Sciences, Sakyo-ku, Kyoto 606-8501, Japan

# Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing

Hirokazu Tamamura,<sup>1</sup> Hiroshi Tsutsumi,<sup>1</sup> Wataru Nomura<sup>1</sup> and Nobutaka Fujii<sup>2</sup>

<sup>1</sup>Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan. <sup>2</sup>Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.

**Abstract:** Seven transmembrane (7TM) G-protein-coupled receptor (GPCR) families are important targets for drug discovery, and specific antagonists for GPCR can accelerate research in the field of medicinal chemistry. The chemokine receptor CXCR4 is a GPCR that possesses a unique ligand CXCL12/stromal cell-derived factor-1 (SDF-1). The interaction between CXCL12 and CXCR4 is essential for the migration of progenitor cells during embryonic development of the cardiovascular, hemopoietic and central nervous systems, and also involved in several intractable disease processes, including HIV infection, cancer cell metastasis, progression of acute and chronic leukemias, rheumatoid arthritis and pulmonary fibrosis. Thus, CXCR4 may be an important therapeutic target in all of these diseases, and various CXCR4 antagonists have been proposed as potential drugs. Fourteen-mer peptides, T140 and its analogs, and downsized cyclic pentapeptides have been developed by us as potent CXCR4 antagonists. This article describes the development of a number of specific CXCR4 antagonists in our laboratory, including downsizing.

**Keywords:** cancer metastasis, chemokine receptor, CXCR4 antagonist, downsizing, HIV infection, rheumatoid arthritis

## Introduction


As a postgenome project, proteomics has been prosperous in life science, and selective ligands involving protein networks have been valuable and useful for studies on chemical biology. Seven transmembrane G-protein-coupled receptors (7TM-GPCRs) are great targets for drug discovery and chemical biology. Thus, development of selective antagonists against each GPCR is extremely desirable (Tamamura and Tsutsumi, 2006). Chemokines are a chemotactic cytokine family that induces migration of leukocytes. Receptors of chemokines, which transduce signals of the corresponding chemokines, are classified into GPCR families. The relationships between chemokines and their receptors are highly interconnected and complicated: in most cases, a single chemokine recognizes a plurality of receptors, and one chemokine receptor recognizes several chemokines. Thus, most of chemokines lack receptor selectivity. However, the chemokine CXCL12/stromal cell-derived factor-1 (SDF-1) possesses the chemokine receptor CXCR4 as its solitary receptor (Tashiro et al. 1993; Nagasawa, Kikutani and Kishimoto, 1994; Oberlin et al. 1996; Bleul et al. 1996). The interaction between CXCL12 and CXCR4 plays a fundamental role in the migration of progenitor cells during embryonic development of the hemopoietic, intestine vascular, cardiovascular and central nervous systems. Its physiological roles in adults remain poorly disclosed. It is also known that the CXCR4-CXCL12 pair is involved in various disease processes such as HIV infection (Feng et al. 1996), cancer cell metastasis (Koshiba et al. 2000; Geminder et al. 2001; Müller et al. 2001; Robledo et al. 2001; Sanz-Rodriguez, Hidalgo and Teixeira, 2001; Scotton et al. 2001; Bertolini et al. 2002; Kijima et al. 2002; Schrader et al. 2002; Scotton et al. 2002; Taichman et al. 2002; Burger et al. 2003; Rubin et al. 2003; Tamamura, Hori et al. 2003; Takenaga et al. 2004; Mori et al. 2004; Piovan et al. 2005; Zannettino et al. 2005), progression of acute and chronic leukemias (Tsukada et al. 2002; Juarez et al. 2003; Burger et al. 2005; Spoo et al. 2007) and rheumatoid arthritis (Nanki et al. 2000) (Fig. 1).

CXCR4 was initially identified as a second receptor (co-receptor) of T cell line-tropic (X4-) HIV-1 entry through its association with the first receptor, CD4. Macrophage-tropic (R5-) HIV-1 strains, which use the chemokine receptor CCR5 as another co-receptor, are major in early stages of HIV infection

**Correspondence:** Hirokazu Tamamura, Tel: 81-3-5280-8036; Email: tamamura.mr@tmd.ac.jp



Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the Creative Commons Attribution By licence. For further information go to: <http://creativecommons.org/licenses/by/3.0/>.



**Figure 1.** Various disorders relevant to the CXCL12-CXCR4 axis, such as HIV infection (i), cancer cell metastasis (ii) and rheumatoid arthritis (iii).

(Alkhatib et al. 1996; Choe et al. 1996; Deng et al. 1996; Doranz et al. 1996; Dragic et al. 1996). However, X4 HIV-1 strains become dominant in the late stages. Recently, it has also been reported that CXCL12 is highly expressed in several internal organs that are the primary targets of cancer cell metastasis, and that CXCR4 is overexpressed on the surfaces of several types of cancer cells. Thus, it has been shown that the CXCL12-CXCR4 axis is associated to metastasis of several types of cancer including cancer of the pancreas, breast,

lung, kidney, and prostate and non-Hodgkin's lymphoma, neuroblastoma, melanoma, ovarian cancer, multiple myeloma and malignant brain tumors. Furthermore, this axis is also correlated to the progression of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). In addition, rheumatoid arthritis (RA) is caused mainly by CD4<sup>+</sup> memory T cell accumulation in the inflamed synovium. It was reported that CXCL12 concentration is extremely elevated in the synovium of RA


patients, and that CXCR4 is highly expressed on the surface of memory T cells. Further, CXCL12 stimulates migration of the memory T cells and thereby inhibits T cell apoptosis. This indicates that the CXCR4-CXCL12 interaction plays an essential role in the accumulation of T cells in the RA synovium. Taken together, CXCR4 is an attractive therapeutic target for these diseases, and our recent research concerning the development of several CXCR4 antagonists including downsizing is discussed in this review article.

### Development of CXCR4 Antagonists as Selective Inhibitors of X4-HIV-1 Entry

Self-defense peptides with antibacterial and antiviral activities, tachyplesins and polyphemusins, have been isolated from the hemocyte debris of the Japanese horseshoe crab (*Tachyplesus tridentatus*) and the American horseshoe crab (*Limulus polyphemus*), which are 17-mer and 18-mer peptides, respectively (Fig. 2) (Nakamura et al. 1988; Miyata et al. 1989). Our preliminary structure-activity relationship studies of these peptides led to the development of T22 ([Tyr<sup>5,12</sup>, Lys<sup>7</sup>]-polyphemusin II) (Masuda et al. 1992; Nakashima et al. 1992) and its downsized 14-mer peptide, T140, which possess strong anti-HIV activity (Fig. 2) (Tamamura et al. 1998). T22 and T140 effectively

block X4-HIV-1 entry into cells by binding specifically to CXCR4, and inhibit Ca<sup>2+</sup> mobilization caused by CXCL12 stimulation against CXCR4 (Murakami et al. 1997; Xu et al. 1999; Murakami et al. 1999). In addition, a T140 analog exhibited a remarkable and significant delaying of the appearance of drug-resistant strains of HIV in passage experiments using cell cultures *in vitro* (Kanbara et al. 2001), and it was presumed that the T140 analogs would be useful for its suppressive effect against drug-resistant strains. Structural analysis revealed that T140 forms an antiparallel  $\beta$ -sheet structure supported by a disulfide bridge between Cys<sup>4</sup> and Cys<sup>13</sup>, which is connected by a type II'  $\beta$ -turn (Tamamura, Sugioka et al. 2001). Four amino acid residues that were contained in T140, Arg<sup>2</sup>, L-3-(2-naphthyl)alanine (Nal)<sup>3</sup>, Tyr<sup>5</sup> and Arg<sup>14</sup>, were identified as residues indispensable for significant activity (Tamamura et al. 2000).

However, T140 is proven to be biologically unstable, and biodegradable in mouse/feline serum or in rat liver homogenate (Tamamura, Omagari et al. 2001; Tamamura, Hiramatsu, Kusano et al. 2003). When indispensable amino acid residues (Arg<sup>14</sup> in serum; Arg<sup>2</sup>, Nal<sup>3</sup> and Arg<sup>14</sup> in liver homogenate) are deleted from the N- and the C-termini, the efficacy of degraded peptides is dramatically reduced. Modification of T140 analogs at both termini efficiently suppresses the above biodegradations and leads to development of novel



**Figure 2.** Structures of tachyplesin I, polyphemusin II, its analog T22, its downsized analog T140, its biostable analogs 4F-benzoyl-TN14003 and 4F-benzoyl-TE14011.

and effective compounds that show highly CXCR4-antagonistic activity as well as increased biological stability. Further studies on the *N*-terminal modification found an electron-deficient aromatic ring such as a 4-fluorobenzoyl moiety at the *N*-terminus to constitute a novel pharmacophore for strong anti-HIV activity. The T140 analogs, which contain an *N*-terminal 4-fluorobenzoyl moiety, 4F-benzoyl-TN14003 and 4F-benzoyl-TE14011, have anti-HIV activity two orders of magnitude higher than that of T140 and enhanced biostability in serum/liver homogenates (Fig. 2) (Tamamura, Hiramatsu, Mizumoto et al. 2003).

### Cyclic Peptides with CXCR4 Antagonistic Activity Derived from T140

Arg<sup>2</sup>, Nal<sup>3</sup>, Tyr<sup>5</sup> and Arg<sup>14</sup> of T140, which are located in close proximity to each other in space,

are indispensable to high antagonistic activity against CXCR4 as described above. For downsizing of T140 analogs, a pharmacophore-guided approach was performed using cyclic pentapeptide libraries, which were composed of two L/D-Arg, L/D-Nal and L/D-Tyr in addition to Gly as a spacer. This approach led to FC131 [*cyclo*(-Arg<sup>1</sup>-Arg<sup>2</sup>-Nal<sup>3</sup>-Gly<sup>4</sup>-D-Tyr<sup>5</sup>-)], which showed strong CXCR4-antagonistic activity comparable to that of T140 (Fig. 3) (Fujii et al. 2003). Structural analysis of FC131 by NMR and simulated annealing molecular dynamics revealed the near-symmetrical pentagonal backbone structure.

A 4-fluorophenyl moiety found as a pharmacophoric moiety as described in the above section was introduced into cyclic pentapeptides. Since replacement of the phenol group of D-Tyr<sup>5</sup> by a 4-fluorophenyl group did not cause the maintenance of high potency, the 4-fluorophenyl group




Figure 3. Structures of cyclic pentapeptides FC131, FC401 and FC602.

was incorporated into position 1. The resulting compound, FC401 ([Phe(4-F)<sup>1</sup>]-FC131), shows significant CXCR4-binding activity (Fig. 3) (Tamamura et al. 2005). Next, since a second Arg residue is thought to be indispensable for high potency and an aromatic residue [L/D-Phe(4-F)] has been incorporated into position 1, four analogs [L/D-Phe(4-F)<sup>1</sup>, L/D-Arg<sup>5</sup>]-FC131 were synthesized based on replacement of D-Tyr<sup>5</sup> by L/D-Arg<sup>5</sup>. Among these analogs, FC602, which is [D-Phe(4-F)<sup>1</sup>, Arg<sup>5</sup>]-FC131, shows the most potent activity, which is 10-fold greater than that of [D-Tyr<sup>1</sup>, Arg<sup>5</sup>]-FC131 (Fig. 3). Thus, FC602 is a novel lead, which involves a pharmacophore moiety different from the pharmacophore groups of FC131.

### A Linear Type of Low Molecular Weight CXCR4 Antagonists

Identification of a novel pharmacophore for CXCR4 antagonism, such as a 4-fluorobenzoyl or 4-fluorophenyl moiety, prompted us to develop a linear type of low molecular weight CXCR4 antagonists. By combining substructure units of the T140 pharmacophore and new pharmacophore moieties, several compounds were designed and

synthesized using combinatorial chemistry. As a result, several linear compounds were found as moderate CXCR4 antagonists, such as compounds 1–3 shown in Figure 4 (Tamamura, Tsutsumi et al. 2006). These compounds are relatively weaker than a cyclic pentapeptide FC131. Thus, it is thought that conformational constriction based on a cyclic pentapeptide scaffold is critical for strong potency.

Anthracene derivatives possessing two sets of zinc(II)-2,2'-dipicolylamine complex were previously found as useful chemosensors that can selectively bind to phosphorylated peptide surfaces (Ojida et al. 2004). Several low molecular weight compounds bearing the complex structure were identified as selective CXCR4 antagonists (Tamamura, Ojida et al. 2006). Molecular superposition of structures of the zinc(II)-2,2'-dipicolylamine complex compound 4 and the cyclic pentapeptide FC131 was investigated as it provided the best fit with the maintenance of local energy minimizations of both of the structures (Fig. 4). The distance between two dipicolylamine moieties of compound 4 is estimated to be nearly equal to that between the two Arg side chains of FC131. Thus, the distance of these functional groups is thought to be




Figure 4. Structures of a linear type of low molecular weight CXCR4 antagonists.



essential for expression of CXCR4 antagonistic activity.

### Anti-Metastasis Activity of T140 Analogs Against Breast Cancer, Melanoma and Pancreatic Cancer

While CXCR4 and another chemokine receptor, CCR7, are highly expressed on the surface of human breast cancer cells, CXCL12 and a CCR7 ligand, CCL21, are highly expressed in lymph nodes, bone marrow, lung and liver, which form the common metastatic destinations of breast cancer. The CXCL12-CXCR4/CCR7-CCL12 axis might determine the metastatic destination of tumor cells and cause organ-preferential metastasis (Müller et al. 2001). Metastasis of breast cancer cells to the lung in mice was inhibited by neutralizing CXCR4 with anti-CXCR4 antibodies. We evaluated the inhibitory activity of our T140 analogs against the migration of breast cancer cells *in vitro* and metastasis of breast cancer cells *in vivo* (Tamamura, Hori et al. 2003). T140 analogs inhibited in dose-dependent manners the migration of a CXCR4-positive human breast carcinoma cell line MDA-MB-231 induced by CXCL12. Furthermore, the inhibitory effect of a bio-stable T140 analog, 4F-benzoyl-TN14003, was confirmed using experimental metastasis models of breast cancer, in which MDA-MB-231 cells were injected intravenously into the tail vein of SCID mice and trapped in the lung to which they migrated through the heart and the pulmonary artery. 4F-benzoyl-TN14003 was subcutaneously injected using an Alzet osmotic pump (DURECT Corp., Cupertino, CA, U.S.A.), and an effective suppression of tumor accumulation was then shown on the lung surface as a result of MDA-MB-231 metastasis. This suggests that small molecule CXCR4 antagonists, such as T140 analogs, can replace anti-CXCR4 antibodies as neutralizers of metastasis of breast cancer.

It was reported that an excessive expression of CXCR4 on B16 melanoma cells enhances the metastatic accumulation of the cells in mouse lung, and that a CXCR4 antagonist T22 blocks pulmonary metastasis in mice injected with CXCR4-transduced B16 cells (Murakami et al. 2002). We found that T140 analogs inhibited pulmonary metastasis in mice injected with B16 cells, which are not transduced with CXCR4 (Takenaga et al. 2004). Poly D,L-lactic acid (PLA) microcapsules containing a T140 analog, 4F-benzoyl-TE14011,

was subcutaneously injected in experimental metastatic models of CXCR4-positive B16-BL6 melanoma cells. 4F-benzoyl-TE14011 is released in a controlled fashion from the PLA microcapsules for a long period *in vivo* with the maintenance of the level of the 4F-benzoyl-TE14011 concentration in bloods. A single subcutaneous administration of 4F-benzoyl-TE14011-PLA significantly decreases the number of colonies ascribed to pulmonary metastasis of B16-BL6 cells. Thus, a controlled release of CXCR4 antagonists might lead to effective suppression of cancer metastasis.

While CXCL12 mRNA is expressed in pancreatic cancer tissues, CXCR4 mRNA is expressed both in pancreatic cancer tissues and in pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, HPAC and PANC-1) (Koshiba et al. 2000). CXCL12 stimulates induction of both migration and invasion of pancreatic cancer cells, AsPC-1, PANC-1 and SUIT-2, in dose-dependent manners *in vitro*. Thus, it suggests that the interaction between CXCL12 and CXCR4 is relevant to pancreatic cancer cell progression and metastasis. CXCL12-induced migration and invasion of these cells are suppressed by T140 analogs in dose-dependent manners (Mori et al. 2004). CXCL12 treatment of PANC-1 cells induces a drastic increase in actin polymerization (cytoskeleton), which causes the invasion and subsequent metastasis of malignant cells into tissues. T140 analogs effectively inhibit this phenomenon.

Furthermore, the CXCL12-CXCR4 axis is relevant to metastasis of SCLC and osteolysis in multiple myeloma. Thus, the blockade of this axis might be an effective remedy against these diseases (Hartmann et al. 2005; Zannettino et al. 2005).

CXCR4 is expressed in malignant cells in at least 23 different types of cancers (Balkwill 2004), including those discussed above. Antagonists of CXCR4 such as the T140 analogs might be useful lead compounds for the development of anti-metastatic agents in several types of cancer.

### Effect of T140 Analogs Against ALL and CLL

Growth and survival of ALL precursor B (pre-B) cells might be caused by mutual contact with bone marrow stromal layers through adhesive interactions between leukemia cells expressing CXCR4 along with integrins and stromal cells expressing CXCL12 and integrin ligands. Migration of these

cells into stromal layers is stimulated by CXCL12, which is constitutively secreted at high levels by marrow stromal cells, since CXCR4 is highly expressed in the pre-B cells. T140 suppresses CXCL12-induced chemotaxis of the cells and attenuates their migration into bone marrow stromal layers. Furthermore, since T140 analogs enhance the cytotoxic and anti-proliferative effects of other anti-cancer agents such as vincristine and dexamethasone, T140 analogs might overcome cell adhesion-mediated drug resistance (CAM-DR) in ALL chemotherapy (Juarez et al. 2003).

On the other hand, B cell CLL, which is the most frequent leukemia in adults in Western countries, is caused by the accumulation of long-lived, monoclonal, malignant B cells in blood, secondary lymphoid organs and bone marrow. CLL B cells that highly express CXCR4 are activated by CXCL12 released from marrow stromal cells or nurse-like cells. CXCL12-stimulation rescues the CLL B cells from apoptosis and contributes to their accumulation. Consequently, the CXCL12-CXCR4 axis should also be a therapeutic target of B cell CLL (Burger et al. 2000). Practically, T140 analogs inhibit chemotaxis of CLL B cells induced by CXCL12, their migration beneath marrow stromal cells and actin polymerization in dose-dependent manners, *in vitro* (Burger et al. 2005). Furthermore, T140 analogs attenuate the anti-apoptotic effect of CXCL12 and prevent stromal cells from protecting against spontaneous apoptosis of CLL B cells. Cocultivation of CLL B cells with marrow stromal cells causes stromal CAM-DR, protecting CLL B cells from undergoing fludarabine-induced apoptosis. Treatment with T140 analogs re-sensitizes these B cells towards fludarabine-induced apoptosis. T140 analogs might overcome CAM-DR which is a serious problem in the clinical CLL chemotherapy.

### Anti-RA Activity of T140 Analogs

The development of biological drugs such as monoclonal antibodies, which target inflammatory cytokines: tumor necrosis factor, TNF- $\alpha$ , interferon, IFN- $\gamma$ , the interleukins, IL-1, IL-6, etc., has brought useful results in clinical RA therapy. However, complete curative effects have not yet been achieved. Thus, other drugs, which are not relevant to the functions of these cytokines, are required to improve RA chemotherapy. Since the CXCR4-CXCL12 axis plays a critical role in the accumula-

tion of memory T cells in the RA synovium (Nanki et al. 2000), anti-RA activity of 4F-benzoyl-TN14003 was evaluated. Delayed-type hypersensitivity (DTH) reaction induced by sheep red blood cells (SRBC) was performed as an *in vivo* experimental model of the cellular immune response (Tamamura et al. 2004). Subcutaneous injection of 4F-benzoyl-TN14003 using an Alzet osmotic pump significantly suppressed the footpad swelling (the DTH response) in dose-dependent manners. Collagen-induced arthritis (CIA) in mice was adopted as the other *in vivo* experimental RA model. Several symptoms of arthritis: score increase, body weight loss, ankle swelling, limb weight gain, etc. were remarkably suppressed. Furthermore, the increase in levels of serum anti-bovine CII IgG2a antibody was apparently suppressed in mice treated with 4F-benzoyl-TN14003 subcutaneously using an Alzet osmotic pump after treatment with the bovine type II collagen (CII) emulsion booster. 4F-benzoyl-TN14003 exhibits an inhibitory effect towards the humoral immune response to CII. Thus, CXCR4 antagonists such as T140 analogs might also be useful leads for anti-RA agents.

### Other CXCR4 Antagonists

Several low molecular weight CXCR4 antagonists, which are not correlated to T140, have been reported to date (Mastrolorenzo, Scozzafava and Supuran, 2001; Scozzafava, Mastrolorenzo and Supuran, 2002). AMD3100 bearing two cyclam groups (Genzyme) (Schols et al. 1997), an *N*-pyridinylmethylene cyclam (monocyclam) AMD3465 (Genzyme) (De Clercq, 2002), AMD8665 without a cyclam group (Genzyme) (Seibert and Sakmar, 2004), AMD070 (Genzyme) (Vermeire et al. 2004), ALX40-4C (Ac-[D-Arg]<sub>9</sub>-NH<sub>2</sub>; NPS Allelix) (Doranz et al. 1997), CGP64222 (Cabrera et al. 2002), R3G (Cabrera et al. 2000), NeoR (Daelmans et al. 2000), a distamycin analog, NSC651016 (Howard et al. 1998) and a flavonoid compound, ampelopsin (Liu et al. 2004), have been identified as CXCR4 antagonists. Conjugates of AMD3100 and galactosylceramide (GalCer) analog have also been found as doubly-functionalized drugs (Daoudi et al. 2004). KRH-1636 (Kureha Chemical and Sankyo) is an orally bioavailable agent possessing *N*-pyridinylmethylene, Arg and naphthalene moieties (Ichiyama et al. 2003). A review of non-T140-related CXCR4 antagonists has been published elsewhere (Tamamura and Fujii, 2005).

## Conclusion

We have found strong anti-HIV agents, T22 and its downsized analog T140, identified as entry inhibitors that bind specifically to the chemokine receptor CXCR4 and thus inhibit entry of X4-HIV-1 to T-cells. T140 and its analogs also show effective activity against cancer metastasis, leukemia and rheumatoid arthritis. Cyclic pentapeptide FC131 was developed as a new low molecular weight CXCR4 antagonist by downsizing of T140. Furthermore, a linear type of low molecular weight CXCR4 antagonists involving aromatic compounds having the zinc(II)-2,2'-dipicolylamine complex structure have been found. These antagonists might be promising agents for clinical chemotherapy of multiple disorders such as HIV infection, cancer metastasis, leukemia and RA. However, blocking of the CXCL12-CXCR4 axis might be a risky procedure because CXCR4 plays a critical role in embryogenesis, homeostasis and inflammation in the fetus especially in the embryonic development of hemopoietic, cardiovascular and central nervous systems. Use of CXCR4 antagonists combined with CCR5 antagonists/fusion inhibitors might lead to a useful candidate for clinical AIDS chemotherapy.

## Acknowledgements

This work was supported in part by a 21st Century COE Program "Knowledge Information Infrastructure for Genome Science", a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Japan Health Science Foundation and The authors wish to acknowledge their collaborators: Profs. Naoki Yamamoto (National Institute of Infectious Diseases/Tokyo Medical and Dental University), Hideki Nakashima (St. Marianna University), Hiroaki Mitsuya (Kumamoto University), Toshio Hattori (Tohoku University), Michinori Waki (Kyushu University), Tsutomu Murakami (National Institute of Infectious Diseases), Ryuichi Doi (Kyoto University), Masayuki Imamura (Kyoto University), Yuetsu Tanaka (University of the Ryukyus), Akira Otaka (The University of Tokushima), Itaru Hamachi (Kyoto University), Linda J. Bendall (University of Sydney), John O. Trent (University of Louisville) and Stephen C. Peiper (Medical College of Georgia), Drs. Tomohiko Mori (Kyoto University), Mitsuko Takenaga (St. Marianna University), Rie Igarashi,

(St. Marianna University), Zixuan Wang (Medical College of Georgia), Jan A. Burger (Freiburg University), Meike Burger (Freiburg University), Andrew C. W. Zannettino (University of Adelaide), Erich Piovon (University of Padua), Jason G. Cyster (University of California San Francisco), Jialin Zheng (University of Nebraska Medical Center), Nikolaus Heveker (Universite de Montreal), Huangui Xiong (University of Nebraska Medical Center), Margitta Retz (University of California San Francisco), Shuichi Kusano (St. Marianna University), Shigemitsu Terakubo (St. Marianna University), Akio Ojida (Kyoto University), Shinya Oishi (Kyoto University), Mr. Kenichi Hiramatsu (Kyoto University), Satoshi Ueda (Kyoto University), Takanobu Araki (Kyoto University), Tomohiro Tanaka (Tokyo Medical and Dental University), Yasuaki Tanabe (Tokyo Medical and Dental University), Ms. Akane Omagari (Kyoto University), Ai Esaka (Kyoto University) and Nami Ohashi (Tokyo Medical and Dental University).

## References

- Alkhatib G., Combadiere C., Broder C.C., et al. 1996. *Science*, 272:1955-8.
- Balkwill, F. 2004. *Semin. Cancer Biol.*, 14:171-9.
- Bertolini, F., Dell'Agnola, C., Mancuso, P. et al. 2002. *Cancer Res.*, 62:3106-12.
- Bleul, C.C., Farzan, M., Choe, H. et al. 1996. *Nature*, 382:829-33.
- Burger, J.A., Tsukada, N., Burger, M. et al. 2000. *Blood*, 96:2655-63.
- Burger, M., Glodek, A., Hartmann, T. et al. 2003. *Oncogene*, 22:8093-101.
- Burger, M., Hartmann, T., Krome, M. et al. 2005. *Blood*, 106:1824-30.
- Cabrera, C., Gutierrez, A., Barretina, J. et al. 2002. *Antiviral Res.*, 53:1-8.
- Cabrera, C., Gutierrez, A., Blanco, J. et al. 2000. *AIDS Res. Hum. Retroviruses*, 16:627-34.
- Choe, H., Farzan, M., Sun, Y. et al. 1996. *Cell*, 85:1135-48.
- Daelemans, D., Schols, D., Witvrouw, M. et al. 2000. *Mol. Pharmacol.*, 57:116-24.
- Daoudi, J.-M., Greiner, J., Aubertin, A.-M. et al. 2004. *Bioorg Med. Chem. Lett.*, 14:495-8.
- De Clercq, E. 2002. *Med. Res. Rev.*, 22:531-65.
- Deng, H.K., Liu, R., Ellmeier, W. et al. 1996. *Nature*, 381:661-6.
- Doranz, B.J., Grovit-Ferbas, K., Sharron, M.P. et al. 1997. *J. Exp. Med.*, 186:1395-400.
- Doranz, B.J., Rucker, J., Yi, Y.J. et al. 1996. *Cell*, 85:1149-58.
- Dragic, T., Litwin, V., Allaway, G.P. et al. 1996. *Nature*, 381:667-73.
- Feng, Y., Broder, C.C., Kennedy, P.E. et al. 1996. *Science*, 272:772-77.
- Fujii, N., Oishi, S., Hiramatsu, K. et al. 2003. *Angew Chem. Int. Ed. Engl.*, 42:3251-3.
- Geminder, H., Sagi-Assif, O., Goldberg, L. et al. 2001. *J. Immunol.*, 167:4747-57.
- Hartmann, T.N., Burger, J.A., Glodek, A. et al. 2005. *Oncogene*, 24:4462-71.
- Howard, O.M.Z., Oppenheim, J.J., Hollingshead, M.G. et al. 1998. *J. Med. Chem.*, 41:2184-93.
- Ichiyama, K., Yokoyama-Kumakura, S., Tanaka, Y. et al. 2003. *Proc. Natl. Acad. Sci. U.S.A.*, 100:4185-90.
- Juarez, J., Bradstock, K.F., Gottlieb, D.J. et al. 2003. *Leukemia*, 17:1294-300.

- Kanbara, K., Sato, S., Tanuma, J. et al. 2001. *AIDS Res. Hum. Retroviruses*, 17:615–22.
- Kijima, T., Maulik, G., Ma, P.C. et al. 2002. *Cancer Res.*, 62:6304–11.
- Koshiba, T., Hosotani, R., Miyamoto, Y. et al. 2000. *Clin. Cancer Res.*, 6:3530–5.
- Liu, D.-Y., Ye, J.-T., Yang, W.-H. et al. 2004. *Biomed Environ Sci.*, 17:153–64.
- Mastrolorenzo, A., Scozzafava, A. and Supuran, C.T. 2001. *Expert Opin. Ther. Pat.*, 11:1245–52.
- Masuda, M., Nakashima, H., Ueda, T. et al. 1992. *Biochem. Biophys. Res. Commun.*, 189:845–50.
- Miyata, T., Tokunaga, F., Yoneya, T. et al. 1989. *J. Biochem.*, 106:663–8.
- Mori, T., Doi, R., Koizumi, M. et al. 2004. *Mol. Cancer Ther.*, 3:29–37.
- Müller, A., Homey, B., Soto, H. et al. 2001. *Nature*, 410:50–6.
- Murakami, T., Maki, W., Cardones, A.R. et al. 2002. *Cancer Res.*, 62:7328–34.
- Murakami, T., Nakajima, T., Koyanagi, Y. et al. 1997. *J. Exp. Med.*, 186:1389–93.
- Murakami, T., Zhang, T.-Y., Koyanagi, Y. et al. 1999. *J. Virol.*, 73:7489–96.
- Nagasawa, T., Kikutani, H. and Kishimoto, T. 1994. *Proc. Natl. Acad. Sci. U.S.A.*, 91:2305–9.
- Nakamura, T., Furunaka, H., Miyata, T. et al. 1988. *J. Biol. Chem.*, 263:16709–13.
- Nakashima, H., Masuda, M., Murakami, T. et al. 1992. *Antimicrob Agents Chemother.*, 36:1249–55.
- Nanki, T., Hayashida, K., El-Gabalawy, H.S. et al. 2000. *J. Immunol.*, 165:6590–8.
- Oberlin, E., Amara, A., Bachelier, F. et al. 1996. *Nature*, 382:833–5.
- Ojida, A., Mito-oka, Y., Sada, K. et al. 2004. *J. Am. Chem. Soc.*, 126:2454–63.
- Piovan, E., Tosello, V., Indraccolo, S. et al. 2005. *Blood*, 105:931–9.
- Robledo, M.M., Bartolome, R.A., Longo, N. et al. 2001. *J. Biol. Chem.*, 276:45098–105.
- Rubin, J.B., Kung, A.L., Klein, R.S. et al. 2003. *Proc. Natl. Acad. Sci. U.S.A.*, 100:13513–8.
- Sanz-Rodriguez, F., Hidalgo, A. and Teixido, J. 2001. *Blood*, 97:346–351.
- Schols, D., Struyf, S., Van Damme, J. et al. 1997. *J. Exp. Med.*, 186:1383–8.
- Schrader, A.J., Lechner, O., Templin, M. et al. 2002. *Br. J. Cancer*, 86:1250–6.
- Scotton, C.J., Wilson, J.L., Milliken, D. et al. 2001. *Cancer Res.*, 61:4961–5.
- Scotton, C.J., Wilson, J.L., Scott, K. et al. 2002. *Cancer Res.*, 62:5930–8.
- Scozzafava, A., Mastrolorenzo, A. and Supuran, C.T. 2002. *J. Enz. Inhib. Med. Chem.*, 17:69–76.
- Seibert, C. and Sakmar, T.P. 2004. *Curr. Pharm. Design.*, 10:2041–62.
- Spoa, A.C., Lübbert, M., Wierda, W.G. et al. 2007. *Blood*, 109:786–91.
- Taichman, R.S., Cooper, C., Keller, E.T. et al. 2002. *Cancer Res.*, 62:1832–7.
- Takenaga, M., Tamamura, H., Hiramatsu, K. et al. 2004. *Biochem. Biophys. Res. Commun.*, 320:226–32.
- Tamamura, H., Esaka, A., Ogawa, T. et al. 2005. *Org. Biomol. Chem.*, 3:4392–4.
- Tamamura, H. and Fujii, N. 2005. *Expert Opin. Ther. Targets*, 9:1267–82.
- Tamamura, H., Fujisawa, M., Hiramatsu, K. et al. 2004. *FEBS Lett.*, 569:99–104.
- Tamamura, H., Hiramatsu, K., Kusano, S. et al. 2003. *Org. Biomol. Chem.*, 1:3656–62.
- Tamamura, H., Hiramatsu, K., Mizumoto, M. et al. 2003. *Org. Biomol. Chem.*, 1:3663–9.
- Tamamura, H., Hori, A., Kanzaki, N. et al. 2003. *FEBS Lett.*, 550:79–83.
- Tamamura, H., Ojida, A., Ogawa, T. et al. 2006. *J. Med. Chem.*, 49:3412–5.
- Tamamura, H., Omagari, A., Hiramatsu, K. et al. 2001. *Bioorg. Med. Chem. Lett.*, 11:1897–902.
- Tamamura, H., Omagari, A., Oishi, S. et al. 2000. *Bioorg. Med. Chem. Lett.*, 10:2633–7.
- Tamamura, H., Sugioaka, M., Odagaki, Y. et al. 2001. *Bioorg. Med. Chem. Lett.*, 11:359–362 and 2409.
- Tamamura, H. and Tsutsumi, H. 2006. *Chem. Biol.*, 13:8–10.
- Tamamura, H., Tsutsumi, H., Masuno, H. et al. 2006. *Org. Biomol. Chem.*, 4:2354–7.
- Tamamura, H., Xu, Y., Hattori, T. et al. 1998. *Biochem. Biophys. Res. Commun.*, 253:877–82.
- Tashiro, K., Tada, H., Heilker, R. et al. 1993. *Science*, 261:600–3.
- Tsukada, N., Burger, J.A., Zvaifler, N.J. et al. 2002. *Blood*, 99:1030–7.
- Vermeire, K., Hatse, S., Princen, K. et al. 2004. *Antiviral Res.*, 62:A42–A43.
- Xu, Y., Tamamura, H., Arakaki, R. et al. 1999. *AIDS Res. Hum. Retroviruses*, 15:419–27.
- Zannettino, A.C.W., Farrugia, A.N., Kortessidis, A. et al. 2005. *Cancer Res.*, 65:1700–9.

## Fluorescent Labeling for PKC delta C1b Domain and Its Application to Sensing Biology

Nami Ohashi<sup>1</sup>, Wataru Nomura<sup>1</sup>, Mai Kato<sup>1,2</sup>, Hiroshi Tsutsumi<sup>1</sup>, Kyoko Itotani<sup>1</sup>, Teikichi Ikura<sup>2</sup>, Nobutoshi Ito<sup>2</sup>, Kiyotsugu Yoshida<sup>3</sup>, Nancy E. Lewin<sup>4</sup>, Peter M. Blumberg<sup>4</sup>, and Hirokazu Tamamura<sup>1,2</sup>

<sup>1</sup>Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan, <sup>2</sup>School of Biomedical Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan, <sup>3</sup>Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan,

<sup>4</sup>Laboratory of Cancer Biology and Genetics, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA

e-mail: tamamura.mr@tmd.ac.jp

*In finding drug lead compounds, development of screening methods, which would be applicable to high-throughput screenings, is an interesting topic. Furthermore, these techniques have potential, which would be used for sensing biological phenomena. This study is focused on the development of an assay method using fluorescence, which targets for PKC that plays important roles in cell signaling pathways and interacts with tumor promoters such as phorbol esters. Herein, the synthesis of ligand binding domains with fluorescent-labeling and their applications are reported.*

**Keywords:** C1 domain, fluorescent-labeling, ligand screening, native chemical ligation, protein kinase C

### Introduction

Protein kinase C (PKC) is phospholipid-dependent serine/threonine-specific protein kinases. In physiological conditions, PKC plays fundamental roles in signaling pathways that regulate cell cycle progression, differentiation, and apoptosis. PKC is also recognized as a receptor for tumor promoters such as phorbol esters. To date, eleven isozymes have been identified for PKC. Each isozyme comprises a catalytic domain and a regulatory domain that contains C1 domains, which form zinc finger structures. PKC activation depends on the binding of ligands such as a diacylglycerol (DAG) and phorbol esters [1]. C1b domains are fairly conserved among the family and known as targets for these ligands. To study the binding properties of currently synthetic ligands or to screen the suitable ligand candidates from vast numbers of compound libraries, a new system for detection of the ligand binding with efficiency and safety (without radio-isotopes) is demanded. Recently, fluorescent dyes are recognized as convenient markers to study the biological functions of proteins or cellular functions. In this study, we have synthesized fluorescent-labeled PKC $\delta$  C1b domain analogs by normal Fmoc solid phase peptide synthesis (Fmoc-SPPS) and

native chemical ligation (NCL). These fluorescent-labeled domains were characterized as molecular markers for ligand bindings (Fig. 1).




Fig. 1. Plausible detection of ligand binding by fluorescent-labeled PKC C1b domain analogs.

## Results and Discussion

For the C1b domain of PKC $\delta$  (221-281), three amino acids (tyrosine at 238, serine at 240, and threonine at 242) were selected as positions for introduction of a fluorescent dye. As a fluorescent dye for this study, a dansyl group was adopted because of its high sensitivity to environmental change and small molecular size. To introduce the dansyl group by Fmoc-SPPS, Fmoc-Lys(dansyl-Gly)-OH was prepared. Each fluorescent-labeled C1b domain analog was successfully synthesized. Ligand bindings of these synthetic C1b domain analogs were evaluated by utilizing [ $^3$ H]-Phorbol 12,13-dibutylate (PDBu). The C1b domain analog, T242K(Dns-G), showed similar binding affinity with that of wild-type. The fluorescence spectra of T242K(Dns-G) in a titration of PDBu are shown in Fig. 2. As an increase of PDBu amount, the fluorescence intensity was increased and fluorescence emission maximum showed blue-shift. This result suggests that the environment of the dansyl group was altered by binding of PDBu to the synthetic C1b domain analog. In conclusion, the present fluorescent-labeled C1b domains enabled us to detect the binding of ligands by an increase of fluorescence intensity and a change of fluorescence emission maximum. The fluorescent-labeled C1b domain analogs would be useful for ligand screening and might be developed as effective biosensors.




Fig. 2. Fluorescence spectra of the fluorescent-labeled C1b domain analog, T242K(Dns-G) in a titration of PDBu (0, 0.2, 0.4, 0.6, 0.8, 1.0, and 1.2 eq.).

## Reference

1. Nishizuka, Y. (1992) *Science*, **258**, 607-614.

## Structure-Activity Relationship Study of CXCR4 Antagonists on the Cyclic Pentapeptide Scaffold: Identification of New Pharmacophore Moieties

Tomohiro Tanaka<sup>1</sup>, Hiroshi Tsutsumi<sup>1</sup>, Wataru Nomura<sup>1</sup>, Yasuaki Tanabe<sup>1,2</sup>, Nami Ohashi<sup>1</sup>, Ai Esaka<sup>3</sup>, Chihiro Ochiai<sup>1</sup>, Jun Sato<sup>1</sup>, Kyoko Itotani<sup>1</sup>, Tsutomu Murakami<sup>4</sup>, Kenji Ohba<sup>4</sup>, Naoki Yamamoto<sup>4</sup>, Nobutaka Fujii<sup>3</sup> and Hirokazu Tamamura<sup>1,2</sup>

<sup>1</sup>Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan, <sup>2</sup>School of Biomedical Science, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan, <sup>3</sup>Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan, <sup>4</sup>AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162-8640, Japan

e-mail: tamamura.mr@tmd.ac.jp

*A highly potent CXCR4 antagonist 2 [cyclo (-D-Tyr1-Arg2-Arg3-Nal4-Gly5-)] has previously been identified by screening cyclic pentapeptide libraries that were designed based on pharmacophore residues of a 14-residue peptidic CXCR4 antagonist 1. In the present study, D-Tyr and Arg in peptide 2 were replaced by a bicyclic aromatic amino acid and a cationic amino acid, respectively, and their binding activity for CXCR4 was evaluated for identification of the novel pharmacophore.*

**Keywords:** CXCR4 antagonists, cationic amino acid, bicyclic aromatic amino acid, FC131

### Introduction

The chemokine receptor CXCR4 is a membrane protein, which belongs to the G-protein coupled receptor family. Interaction of CXCR4 with its endogenous ligand stromal-cell derived factor-1 $\alpha$  (SDF-1 $\alpha$ )/CXCL12 induces various physiological functions: chemotaxis, angiogenesis, neurogenesis etc. in embryonic stage. On the other hand, CXCR4 is also relevant to multiple diseases: AIDS, cancer metastasis, progress of leukemia, rheumatoid arthritis, etc. in adulthood. Actually, CXCR4 has been reported to be a potential drug target against these diseases. Thus, CXCR4 antagonists are useful for development of potent therapeutic agents against these diseases. A  $\beta$ -sheet-like 14-residue peptide **1** was previously identified by structure optimization of an 18-residue cyclic peptide polyphemusin isolated from horseshoe crabs. In the downsizing of **1**, a cyclic pentapeptide **2** was developed by screening libraries based on four pharmacophore residues [Arg, Arg, 3-(2-naphthyl)alanine (Nal), D-Tyr] found by alanine scanning of **1**. (Fig. 1)




Fig. 1. Development of a cyclic pentapeptide 2 based the pharmacophore of a CXCR4 antagonistic peptide 1. Cit = *l*-citrulline, Nal = *l*-3-(2-naphthyl)alanine.

## Results and Discussion

Our previous data of alanine-scanning of 2 suggested that D-Tyr<sup>1</sup> or Arg<sup>2</sup> was not optimized [1]. Thus, we attempted to replace these functional groups. According to other previous reports, potent CXCR4 antagonists absolutely contain aromatic and




Fig. 2. Structures of compounds having substitution of an LD-bicyclic aromatic amino acid for D-Tyr<sup>1</sup>.




Fig. 3 Structures of compounds having LD-Arg<sup>1</sup> and an LD-bicyclic aromatic amino acid<sup>2</sup>.



cationic groups. It suggests that these functional groups are involved in binding to CXCR4 mediated by hydrophobic and electrostatic interaction. In our first approach, D-Tyr<sup>1</sup> of **2** was replaced by an L/D-bicyclic aromatic amino acid to evaluate significance of the hydrophobic interaction by aromatic rings. In addition, four epimers were synthesized to evaluate effects of configuration of amino acids of the 1- and 2- positions (Fig. 2). Compounds **3c** and **3d** with replacement of D-Tyr<sup>1</sup> by D-3-(1-naphthyl)alanine (D-Nal(1)) showed high CXCR4 binding activity ( $IC_{50}$  = 0.043 and 0.078  $\mu$ M, respectively, Table 1), although the potencies were approximately one-third or fifth of that of the parent compound **2** ( $IC_{50}$  = 0.015  $\mu$ M, Table 1). Similarly, compounds **5c** and **5d**, replaced by D-Trp at the 1-position, showed 5-10 fold lower CXCR4 binding activity ( $IC_{50}$  = 0.15 and 0.070  $\mu$ M, respectively, Table 1) than the parent compound **2**. On the other hand, compounds **4c** and **4d** did not show strong CXCR4 binding activity. These data indicates that the spatial position of aromatic ring is essential for the expression of CXCR4 binding activity.

An analogue of **2**, having substitution of Arg<sup>1</sup> and D-4F-phenylalanine<sup>2</sup> for D-Tyr<sup>1</sup> and Arg<sup>2</sup>, respectively, was recently found as a strong CXCR4 antagonist [2]. To evaluate effects of the sequential difference of cationic and aromatic groups at the 1- and 2-positions on CXCR4 binding activity, Arg and a large aromatic amino acid (Nal(1), Nal or Trp) were shuffled in the pentapeptide, and four epimers were synthesized in a similar manner (Fig. 3). Synthetic compounds except for **7b** did not show CXCR4 binding activity up to 0.3  $\mu$ M (Table 1). In particular, a series of **6** and **8** did not show CXCR4 binding activity despite of difference of the chirality of amino acids at the 1- and 2-positions (**6c**, **8d** >0.3 mM, **6a**, **6b**, **6d**, **8a**, **8b**, **8c** > 2.0  $\mu$ M). On the other hand, a series of **7**, which introduced L/D-Nal at the 2-position, did not show a serious reduction of CXCR4 binding activity.

Each synthetic compounds were evaluated to CXCR4 binding ( $IC_{50}$ ) by competition assay utilized radio-isotope labeled SDF-1 $\alpha$  (Table 1). In addition, several compound that showed high CXCR4 binding activity were evaluated anti-HIV activity and cytotoxicity.(Table 2)

## Conclusion

Our first approach screening cyclic pentapeptides, which have substitution of a bicyclic aromatic amino acid at the 1-position, disclosed that D-3-(1-naphthyl)alanine and D-Trp at the 1- position might be alternative pharmacophore moieties, and that


**Table 1** inhibitory activity of the synthetic compounds against binding of [<sup>125</sup>I]-SDF-1 $\alpha$  to CXCR4

Compound	$IC_{50}/\mu$ M	Compound	$IC_{50}/\mu$ M	Compound	$IC_{50}/\mu$ M	Compound	$IC_{50}/\mu$ M
<b>2</b>	0.015	<b>3c</b>	0.043	<b>6a</b>	> 2.0	<b>6c</b>	0.3 - 2.0
<b>3a</b>	0.3 - 2.0	<b>4c</b>	> 2.0	<b>7a</b>	0.3 - 2.0	<b>7c</b>	0.3-2.0
<b>4a</b>	0.3-2.0	<b>5c</b>	0.15	<b>8a</b>	> 2.0	<b>8c</b>	> 2.0
<b>5a</b>	0.22	<b>3d</b>	0.078	<b>6b</b>	> 2.0	<b>6d</b>	> 2.0
<b>3b</b>	0.3 - 2.0	<b>4d</b>	0.3 - 2.0	<b>7b</b>	0.045	<b>7d</b>	0.3 - 2.0
<b>4b</b>	0.3 - 2.0	<b>5d</b>	0.07	<b>8b</b>	> 2.0	<b>8d</b>	0.3 - 2.0
<b>5b</b>	> 2.0						

Table 2 Anti-HIV activity and cytotoxicity of the synthetic compounds

Compound	EC <sub>50</sub> /mM <sup>a</sup>	CC <sub>50</sub> /μM <sup>b</sup>
AZT	0.077	>10
1	0.044	>10
2	0.15	>10
5c	0.7	>10
5d	0.19	>10
7b	0.26	>10

introduction of D-amino acid at the 1-position was required to form an optimal cyclic pentapeptide backbone. A cyclic pentapeptide library based on shuffling cationic and aromatic amino acids at the 1- and 2-positions of compound 2 was designed. As a result, the order of a cationic amino acid and an aromatic amino acid is significant to maintain strong CXCR4 binding activity of analogues of 2. Compound 7b, however, showed the highest CXCR4 binding activity among the present synthetic cyclic pentapeptides. 7b was proven to be a new type lead, because of the difference of the order of cationic and aromatic residues, and also showed high anti-HIV activity. Finding of compound 7b indicated that Arg<sup>1</sup> and *p*-Nal<sup>2</sup> may be novel pharmacophore moieties in the combination with Nal<sup>4</sup> and Arg<sup>3</sup>. The present data will provide useful approaches for simple designs of new lowmolecular weight CXCR4 antagonists. These results might also give valuable insights for understanding the ligand-receptor interactions.



## References

- Ueda, S., Oishi, S., Wang, Z., Araki, T., Tamamura, H., Cluzeau, J., Ohno, H., Kusano, S., Nakashima, H., Trent, J. O., Peiper, S. C. and Fujii, N. (2007) *J. Med. Chem.*, **50**, 192-198.
- Tamamura, H., Esaka, A., Ogawa, T., Araki, T., Ueda, S., Wang, Z., Trent, J. O., Tsutsumi, H., Masuno, H., Nakashima, H., Yamamoto, N., Peiper, S. C., Otaka, A. and Fujii, N. (2005) *Org. Biomol. Chem.*, **3**, 4392-4394.

## Small-Sized CD4 Mimics Targeted for Dynamic Supramolecular Mechanism of HIV-1 Entry

Chihiro Ochiai<sup>1</sup>, Yuko Yamada<sup>1</sup>, Kazuhisa Yoshimura<sup>2</sup>, Tomohiro Tanaka<sup>1</sup>, Hiroshi Tsutsumi<sup>1</sup>, Wataru Nomura<sup>1</sup>, Hiroyuki Masuno<sup>1</sup>, Kyoko Itotani<sup>1</sup>, Junji Shibata<sup>2</sup>, Makiko Hatada<sup>2</sup>, Shuzo Matsushita<sup>2</sup>, and Hirokazu Tamamura<sup>1,3</sup>

*Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan, <sup>2</sup>Center for AIDS Research, Kumamoto University, Kumamoto 860-0811, Japan, <sup>3</sup>School of Biomedical Science, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan*  
e-mail: tamamura.mr@tmd.ac.jp

*The elucidation of the dynamic supramolecular mechanism in HIV entry has provided insights into new type of drugs that can block HIV infection. In this study, we focused on CD4 mimic small compounds, such as NBD-556, and performed their structure-activity relationship study. In addition, it was found that CD4 mimic compounds have a great effect on the dynamic supramolecular mechanism of HIV entry, and that their combinational use with CXCR4 antagonists or neutralizing antibodies shows a synergic effect.*

**Keywords:** CD4 mimic, CXCR4 antagonists, dynamic supramolecular mechanism, HIV entry, synergic effect

### Introduction

Recently, as the clinical treatment of HIV-infected and AIDS patients, "highly active anti-retroviral therapy (HAART)", which involves a combination of two or three agents that are usually adopted from two categories composed of reverse transcriptase inhibitors and protease inhibitors, has brought us a tremendous success. Furthermore, a molecular mechanism involved in HIV-entry and -fusion into host cells has been disclosed in detail (Fig. 1). A fusion inhibitor, enfuvirtide (fuzeon, Trimeris & Roche), a CCR5 antagonist, maraviroc (Pfizer) and an integrase inhibitor, raltegravir (Merck) have also been clinically used in USA. However, serious problems still remain even with the chemotherapy, such as the emergence of viral strains with multi-drug resistance (MDR), considerable adverse effects and high costs. Thus, development of novel drugs possessing action mechanisms different from the above inhibitors would be currently required. We have previously developed selective antagonists against the chemokine receptor CXCR4, which is the co-receptor of an X4-HIV-1 entry [1]. In the present study, we focus on the development of CD4 mimic compounds based on NBD-556 [2] (Fig. 2). In addition, we investigate an effect of CD4 mimic compounds on conformational change of an HIV surface protein, gp120 (Fig. 1).




Fig. 1. Plausible mechanism for the dynamic supramolecular mechanism in HIV-entry and -fusion. The binding of a cell surface protein CD4 to an HIV surface protein gp120 causes a conformational change of gp120 and an increase in binding affinity of anti-gp120-V3 antibody for gp120.




Fig. 2. A structure of CD4 mimic compounds. X = halogen, alkyl or nitro group (X = Cl: NBD-556).

## Results and Discussion

It is speculated that there is a large space around the *p*-position of the phenyl ring of NBD-556, which might interact with a cavity of a viral surface protein gp120. Thus, NBD analogues having various substituents on the phenyl ring were synthesized (Fig. 2). Several compounds showed potent anti-HIV activity (data not shown). In addition, NBD analogues showed highly synergic effects not only with an anti-V3 antibody but also with T140. FACS analysis showed that in the presence of NBD analogues the anti-V3 antibody strongly binds to the HIV envelope.

CD4 mimic compounds might expose the coreceptor-binding region of gp120, which was hidden inside. These compounds would be important probes directed to the dynamic supramolecular mechanism of HIV Entry, and useful lead compounds for cocktail therapy of AIDS.

## References

1. Tamamura, H., Tsutsumi, H., Nomura, W., Tanaka, T., and Fujii, N. (2008) *Expert Opin. Drug Discov.*, **3**, 1155-1166.
2. Schön, A., Madani, N., Klein, J. C., Hubicki, A., Ng, D., Yang, X., Smith, A. B., III, Sodroski, J., and Freire, E. (2006) *Biochemistry*, **45**, 10973-10980.